

Table I.
Gram-Negative Bacilli [1]

Norton Hospital
2022

| | | | Number Tested | Penicillins | Cephalosporins | Monobactam | Carbapenems | Aminoglycosides | Others |
|--|-----|-----------|---------------|---|--|--|-------------------|-------------------|------------------|
| <i>Acinetobacter baumannii</i> complex [5] | 17 | R R | 59 | Ampicillin Amoxicillin/Clavulanate Ampicillin/Sulbactam Piperacillin/Tazobactam (%S) [2] | R 65 Oral cephalosporins for uncomplicated UTI Cefazolin | R 76 Cefepime (%S) [3] Cefepime (%SDD) [3] | R 65 Aztreonam | R 65 Ertapenem | R 65 Amikacin |
| <i>Citrobacter freundii</i> complex [6] | 35 | R R R | 100 0 | R 100 0 | R 83 74 | 81 | 100 100 | 100 97 94 | * * 100 94 |
| <i>Citrobacter koseri</i> | 27 | R 100 | 96 * | 89 100 0 | 96 96 | 96 | 100 100 | 100 100 100 | * * 79 100 |
| <i>Enterobacter cloacae</i> complex [7] | 124 | R R R | 68 4 | R 78 6 | 62 56 | 65 | 88 100 | 100 95 95 | 87 87 35 85 |
| <i>Escherichia coli</i> | 961 | 44 83 | 53 96 1 | 82 63 88 1 | 89 86 | 86 | 99 99 | 99 90 91 | 73 77 95 72 |
| <i>Klebsiella aerogenes</i> | 41 | R R R | 79 14 | R 93 2 | 60 54 | 64 | 98 100 | 100 100 100 | 91 91 9 98 |
| <i>Klebsiella oxytoca</i> | 61 | R 85 | 64 * | 15 91 2 | 91 84 | 87 | 100 100 | 100 93 95 | 90 90 75 87 |
| <i>Klebsiella pneumoniae</i> | 273 | R 91 | 68 91 1 | 77 70 79 2 | 79 79 | 80 | 99 99 | 100 96 95 | 69 81 41 86 |
| <i>Morganella morganii</i> | 33 | R R | 6 100 0 | R 100 0 | 70 82 | 77 | 100 100 | 100 94 97 | 80 80 R 85 |
| <i>Proteus mirabilis</i> | 128 | 83 95 | 92 100 0 | 92 72 97 1 | 97 97 | 90 | 100 100 | 97 92 92 | 88 88 R 84 |
| <i>Proteus vulgaris</i> | 22 | R 91 | 64 * | R 82 5 | 86 32 | 39 | 100 100 | 100 100 100 | * * R 100 |
| <i>Pseudomonas aeruginosa</i> | 196 | R R R | 87 | R 87 | 90 R | 80 | R 89 | 95 86 99 | 87 85 R R |
| <i>Serratia marcescens</i> | 45 | R R R | 69 6 | R 84 13 | 49 53 | 60 | 100 100 | 100 96 87 | 64 64 R 93 |
| <i>Stenotrophomonas maltophilia</i> | 32 | R R R R R | R | R 28 R | R | R R | R R R | 97 100 | |

For antimicrobials listed, number shown is the percentage of unique isolates susceptible by current CLSI breakpoints, unless otherwise noted.

Please exercise discretion when data are reviewed for species with fewer than 30 isolates due to reduced statistical validity.

*Data is not shown for species or species/antimicrobial combinations that have fewer than 10 isolates.

A value of R indicates that this organism is intrinsically resistant to the antimicrobial agent.

[1] All organisms in this table are intrinsically resistant to oxacillin, penicillin, clindamycin, erythromycin, vancomycin, linezolid, and daptomycin.

[2] Interpretation of Susceptible (S) is based on dosage regimen of 3.375-4.5g administered every 6 h as a 30 minute infusion. Interpretation of Susceptible Dose-Dependent (SDD) is based on a dosage regimen of 4.5g administered every 6 h as a 3 hour infusion or 4.5g administered every 8 hour as a 4 hour infusion.

[3] Interpretation of Susceptible (S) is based on dosage regimen of 1g administered every 12 hours. Interpretation of Susceptible Dose-Dependent (SDD) is based on 1-2 g administered every 8-12 hours.

[4] Nitrofurantoin susceptibility is based on urine isolates only.

[5] *A. baumannii* complex consists of the species *A. baumannii*, *A. calcoaceticus*, *A. nosocomialis*, and *A. pitii*.

[6] *C. freundii* complex consists of the species *C. braakii*, *C. freundii*, *C. murliniae*, *C. sedlaki*, *C. werkmanii*, and *C. youngae*.

[7] *E. cloacae* complex consists of the species *E. asburiae*, *E. cloacae*, *E. hormaechei*, *E. kobei*, *E. ludwigii*, and *E. nimipressuralis*.

Table II.
Gram-Positive Cocci [1]
Norton Hospital 2022

| | Number Tested | Penicillins | | | Cephalosporins | | | Gram + Coverage | | | | Others | | | | | |
|--|---------------|-------------------------|------------|-----------|----------------|-----------|-------------|--------------------|-------------------|------------------|------------|-----------|----------------|--------------|--------------------|--------------|---------------|
| | | Amoxicillin/Clavulanate | Ampicillin | Oxacillin | Penicillin | Cefazolin | Ceftriaxone | Gentamicin Synergy | Clindamycin [2,3] | Erythromycin [3] | Vancomycin | Linezolid | Daptomycin [4] | Levofloxacin | Nitrofurantoin [3] | Tetracycline | Trimeth/Sulfa |
| <i>Staphylococcus aureus</i> | 589 | 46 | | 46 | | 46 | | | 75 | 31 | 100 | 100 | 99 | | | 94 | 97 |
| Methicillin-resistant <i>S. aureus</i> | 317 | 0 | | 0 | | 0 | | | 74 | 13 | 100 | 100 | 99 | | | 94 | 97 |
| Methicillin-susceptible <i>S. aureus</i> | 272 | 100 | | 100 | | 100 | | | 77 | 52 | 100 | 100 | 100 | | | 93 | 99 |
| <i>Staphylococcus epidermidis</i> | 139 | 32 | | 32 | | 32 | | | 49 | 29 | 100 | 100 | 100 | | 98 | 81 | 57 |
| <i>Staphylococcus haemolyticus</i> | 11 | 55 | | 55 | | 55 | | | * | * | 100 | 100 | 100 | | * | 82 | 64 |
| <i>Staphylococcus hominis</i> | 11 | 64 | | 64 | | 64 | | | * | * | 100 | 100 | 100 | | * | 73 | 82 |
| <i>Staphylococcus lugdunensis</i> | 27 | 74 | | 74 | | 74 | | | 79 | 58 | 100 | 100 | 100 | | * | 89 | 96 |
| Other coagulase-negative staphylococci | 25 | 64 | | 64 | | 64 | | | 65 | 60 | 100 | 100 | 100 | | * | 96 | 96 |
| <i>Enterococcus faecalis</i> | 164 | | 98 | | 98 | R | R | 85 | R | 33 | 95 | 99 | 100 | | * | 37 | R |
| <i>Enterococcus faecium</i> | 50 | | 38 | | 34 | R | R | 92 | R | 13 | 46 | 100 | 92 (SDD) | | * | 34 | R |
| Other <i>Enterococcus</i> species | 15 | | 73 | | 73 | R | R | 100 | R | 75 | 80 | 100 | 100 | | * | 40 | R |
| Group B <i>Streptococcus</i> (<i>S. agalactiae</i>) | 28 | | 100 | | 100 | | | 100 | | 43 | 32 | 100 | | 100 | | 14 | R |
| <i>Streptococcus anginosus</i> [5] | 68 | | 99 | | 99 | | | 100 | | 75 | 50 | 100 | | 100 | | 35 | |
| <i>Streptococcus constellatus</i> [5] | 35 | | 100 | | 97 | | | 100 | | 77 | 74 | 100 | | 100 | | 49 | |
| <i>Streptococcus intermedius</i> [5] | 29 | | 96 | | 100 | | | 100 | | 93 | 81 | 100 | | 100 | | 78 | |
| <i>Streptococcus pneumoniae</i> | 34 | 97 | | | See Table III | | | See Table III | | 91 | 62 | 100 | | 100 | | 97 | 82 |
| <i>Streptococcus pyogenes</i> | 19 | | 100 | | 100 | | | 100 | | 84 | 79 | 100 | | 100 | | 74 | R |
| <i>Viridans streptococci</i> | 41 | | 78 | | 73 | | | 98 | | 86 | 46 | 100 | | 95 | | 59 | |
| <i>Aerococcus urinae</i> | 22 | | 95 | | 98 | | | 100 | | * | * | 100 | | 68 | | 77 | R |

For antimicrobials listed, number shown is the percentage of unique isolates susceptible by current CLSI breakpoints, unless otherwise noted.

Please exercise discretion when data are reviewed for species with fewer than 30 isolates due to reduced statistical validity.

*Data is not shown for species or species/antimicrobial combinations that have fewer than 10 isolates.

A value of R indicates that this organism is intrinsically resistant to the antimicrobial agent.

[1] All organisms in this table are intrinsically resistant to aztreonam.

[2] MRSA: 6% inducible resistance, 20% constitutive resistance; MSSA: 18% inducible resistance, 5% constitutive resistance; Coag-neg Staph (all species): 4% inducible resistance, 37% constitutive resistance.

[3] Clindamycin and erythromycin data are based on non-urine isolates only. Nitrofurantoin susceptibility is based on urine isolates only.

[4] For *E. faecium* only, daptomycin interpretation of SDD is based on dosage regimen of 8-12 mg/kg administered every 24 hours and is intended for serious *E. faecium* infections only. There is no S category for *E. faecium* with daptomycin. For other *Enterococcus* species, daptomycin interpretation of S is based on a dosage regimen of 6 mg/kg administered every 24 hours.

[5] *S. anginosus*, *S. constellatus*, and *S. intermedius* together comprise the *S. anginosus* complex.

Table III.
Streptococcus
pneumoniae
Penicillin & Ceftriaxone
Norton Hospital 2022

| | Penicillin - IV meningitis | Penicillin - IV non-meningitis | Penicillin - Oral | Ceftriaxone - IV meningitis | Ceftriaxone - IV non-meningitis |
|-----------------------------|----------------------------|--------------------------------|-------------------|-----------------------------|---------------------------------|
| Percent Susceptible | 79 | 100 | 79 | 91 | 97 |
| Percent Intermediate | - | 0 | 12 | 6 | 3 |
| Percent Resistant | 21 | 0 | 9 | 3 | 0 |